Researcher.Life Logo

Drugs - Real World Outcomes : Impact Factor & More

eISSN: 2198-9788pISSN: 2199-1154
JournalOpen Access

Key Metrics

CiteScore
2.7
H-Index
19
SJR
Q2Pharmacology (medical)
SNIP
0.87
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Drugs - Real World Outcomes

Drugs - Real World Outcomes Journal Specifications

Overview
Publisher SPRINGERNATURE
Language English
Frequency Quarterly
Article Processing ChargesEUR 2190 | USD 2690 | GBP 1890
Publication Time8
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyQuarterly
Publication Start Year2014
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 8
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY-NC
OA statementVisit website
View less

Planning to publish in Drugs - Real World Outcomes ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Drugs - Real World Outcomes

Assessment of Potential Drug-Drug Interactions and Associated Factors Among Pulmonary Inpatients in a Tertiary Care Hospital: A Cross-Sectional Study.
  • 25 Jun 2026
  • Drugs - real world outcomes
Characteristics and Future Perspectives of Available Electronic Health Record Databases in Japan.
  • 24 Jun 2026
  • Drugs - real world outcomes
The Long-Term Sequelae and Clinical Workload Resulting from Toxicities of Immune Checkpoint Inhibitor (ICI) Therapy in Patients with Cancer.
  • 23 Jun 2026
  • Drugs - real world outcomes
Long-Term Antidepressant Use and Dementia Risk: A Propensity Score-Matched Study of Swiss Older Adults, with an Anticholinergic-Specific Analysis.
  • 10 Jun 2026
  • Drugs - real world outcomes
Real-World Evidence for Drug Value Assessment in China: Learning from International Experiences
  • 4 Jun 2026
  • Drugs - Real World Outcomes
Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Na\xefve Patients and Switchers in a Multicenter Cohort
  • 31 May 2026
  • Drugs - Real World Outcomes
Assessment of Potential Drug-Drug Interactions and Associated Factors Among Pulmonary Inpatients in a Tertiary Care Hospital: A Cross-Sectional Study.
  • 25 Jun 2026
  • Drugs - real world outcomes
Characteristics and Future Perspectives of Available Electronic Health Record Databases in Japan.
  • 24 Jun 2026
  • Drugs - real world outcomes
The Long-Term Sequelae and Clinical Workload Resulting from Toxicities of Immune Checkpoint Inhibitor (ICI) Therapy in Patients with Cancer.
  • 23 Jun 2026
  • Drugs - real world outcomes
Long-Term Antidepressant Use and Dementia Risk: A Propensity Score-Matched Study of Swiss Older Adults, with an Anticholinergic-Specific Analysis.
  • 10 Jun 2026
  • Drugs - real world outcomes
Real-World Evidence for Drug Value Assessment in China: Learning from International Experiences
  • 4 Jun 2026
  • Drugs - Real World Outcomes
Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Na\xefve Patients and Switchers in a Multicenter Cohort
  • 31 May 2026
  • Drugs - Real World Outcomes

FAQs on Drugs - Real World Outcomes